microRNA 1260b (miR-1260b)

MicroRNA 1260b (miR-1260b) is a non-coding RNA molecule that acts post-transcriptionally to repress or degrade target mRNAs. It is upregulated in various cancers, including non-small cell lung cancer, prostate cancer, colorectal cancer, hepatocellular carcinoma, and renal cell carcinoma. miR-1260b promotes cell proliferation, drives cell cycle progression, suppresses apoptosis and cellular senescence, and contributes to tumorigenesis by targeting negative regulators such as SOCS6 (activating KIT signaling) and SFRP1 (activating the Wnt pathway)[1][2]. It also mediates chemoresistance to taxane-based therapies by decreasing sensitivity to drugs like paclitaxel and docetaxel[2]. miR-1260b serves as a potential biomarker for cancer diagnosis and progression, particularly in NSCLC, due to its elevated levels in patient plasma and tumor tissue. It is under investigation both as a molecular marker and as a candidate for therapeutic targeting to overcome chemoresistance[1][2].

Other names

hsa-miR-1260bhsa-mir-1260bmir-1260bMIR1260B

Downregulation of miR-1260b increases sensitivity to taxanes (restores chemosensitivity). Upregulation of miR-1260b promotes drug resistance. It also regulates oncogenic pathways, such as the Wnt pathway via SFRP1 suppression and KIT signaling via SOCS6 targeting.